Moving Beyond Chemotherapy in Metastatic Triple-Negative Breast Cancer (mTNBC): Are We Clinically Ready? (non-accredited)

This live debate examines whether clinicians are ready to move beyond chemotherapy as the default first consideration for metastatic triple-negative breast cancer (mTNBC), focusing on the urgency of treatment decisions, emerging antibody–drug conjugate (ADC) data, and real-world feasibility. Expert faculty will weigh the clinical promise of ADCs against ongoing concerns around toxicity management, data interpretation, and variability in community practice. Through point–counterpoint discussion and case-based scenarios, the program highlights the practical, evidence-driven tensions shaping treatment sequencing in mTNBC today. Supported by funding from Gilead. All content developed independently by HMP Global.